Navigation Links
Westaim announces 2008 third quarter results
Date:11/12/2008

CALGARY, Nov. 12 /PRNewswire-FirstCall/ - The Westaim Corporation announced today that for the third quarter ended September 30, 2008, it recorded a net loss of $3.1 million or 3 cents per share, on revenues of $5.5 million. In the same quarter last year, the Company recorded a net loss of $17.1 million, or 18 cents per share, on revenues of $7.8 million.

The loss from continuing operations was $1.9 million for the quarter compared to a loss of $8.8 million in the same period in 2007. Included in the 2008 loss was a write-down of $0.9 million in the value of the Company's investment in Canadian third party asset-backed commercial paper (ABCP) compared to a write-down of $3.0 million in the third quarter of 2007. The third quarter of 2008 benefitted from lower corporate costs compared to 2007 as a result of reduced operations and $2.3 million of severance costs included in the 2007 results. The loss from discontinued operations, which includes windup and operating costs at the Company's wholly owned subsidiary, iFire Technology Ltd., declined significantly to $1.3 million compared to $8.4 million in the third quarter of 2007.

For the nine months ended September 30, 2008, the Company posted a net loss of $13.0 million or 14 cents per share on revenues of $15.4 million. For the same period in 2007, Westaim reported a net loss of $31.2 million or 33 cents per share on revenues of $20.7 million.

The loss from continuing operations for the nine months ended September 30, 2008 was $0.5 million compared to a loss of $4.0 million for the same period in 2007. Results from continuing operations in 2008 benefitted from a dilution gain of $6.0 million relating to the sale of a non-core subsidiary, a $4.6 million improvement in foreign exchange gains and losses and in 2007 benefitted from the $8.6 million gain on the sale of the Company's real estate assets in Fort Saskatchewan, Alberta and a dilution gain of $4.5 million. The loss from discontinued operations for the first nine months of 2008 was $12.5 million reflecting a write-down of capital assets of $7.1 million as well as severance and other windup costs at iFire, compared to a loss of $27.2 million for the first nine months of 2007.

At September 30, 2008, Westaim had $39.1 million in consolidated cash and short-term investments. Westaim's cash position, excluding cash and short-term investments held by its 74.5 per cent owned affiliate NUCRYST Pharmaceuticals Corp., was $11.3 million. In addition, Westaim held third-party ABCP with a book value of $5.1 million.

"Proceeds from the previously announced sale of iFire's assets has strengthened the Company's cash position as we examine Westaim's corporate structure moving forward," said Drew Fitch, President & CEO of The Westaim Corporation. "Westaim's Board of Directors has made a number of strategic decisions over the course of the past few months and will continue to examine all possible options in a concerted effort to maximize shareholder value."

The Westaim Corporation's common shares are listed on The Toronto Stock Exchange under the trading symbol WED. Westaim holds a 74.5 percent interest in NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS).

This news release contains forward-looking statements. These statements are based on current expectations that are subject to risks and uncertainties, and Westaim can give no assurance that these expectations are correct. Various factors could cause actual results to differ materially from those projected in such statements, including but not limited to statements regarding Westaim's examination of its corporate structure, and the Company's examination of all possible options in a concerted effort to maximize shareholder value. Westaim disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise. Accordingly, readers are advised not to place undue reliance on forward-looking statements, and should not rely on this information at any date other than the date of this news release. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

THE WESTAIM CORPORATION

Financial Highlights

(unaudited)

(thousands of dollars except per share data)

-------------------------------------------------------------------------

Three Months Ended Nine Months Ended

September 30 September 30

Consolidated Statements ------------------- -------------------

of Operations 2008 2007 2008 2007

-------------------------------------------------------------------------

Revenue $ 5,466 $ 7,839 $ 15,428 $ 20,656

Loss from continuing operations (1,851) (8,773) (511) (3,996)

Net loss (3,122) (17,138) (12,981) (31,226)

Net loss per common share

- basic and diluted

Continuing operations (0.02) (0.09) (0.01) (0.04)

Net loss (0.03) (0.18) (0.14) (0.33)

Weighted average number of common

shares outstanding (thousands) 94,215 94,098 94,205 94,047

-------------------------------------------------------------------------

Three Months Ended Nine Months Ended

September 30 September 30

------------------- -------------------

Segmented Information 2008 2007 2008 2007

-------------------------------------------------------------------------

Revenue from continuing

operations

Nucryst Pharmaceuticals $ 5,466 $ 7,839 $ 15,428 $ 20,656

-------------------------------------------------------------------------

-------------------------------------------------------------------------

(Loss) income from continuing

operations

Nucryst Pharmaceuticals $ (114) $ (2,479) $ (4,133) $ (7,980)

Other (including corporate

costs) (1,737) (6,294) 3,622 3,984

-------------------------------------------------------------------------

Loss from continuing operations $(1,851) $ (8,773) $ (511) $ (3,996)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Consolidated Balance Sheets September December

30, 2008 31, 2007

-----------------------------------------------------

Cash and cash equivalents $ 39,147 $ 30,993

Current assets 50,249 51,561

Other assets 23,211 31,826

Current liabilities 11,141 8,461

Shareholders' equity 44,989 56,371


'/>"/>
SOURCE Westaim Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Third Quarter Results
2. Westaim terminates reorganization agreement and cancels shareholders meeting
3. Westaim to deregister its common stock in the United States
4. Westaim announces sale of iFire Technology Ltd. assets
5. Westaim announces 2008 second quarter results
6. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Second Quarter Results
7. Westaim announces 2008 first quarter results
8. Webcast Advisory - The Westaim Corporation Webcast of Annual Meeting of Shareholders
9. Westaim announces 2007 year-end results
10. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Fourth Quarter Results
11. Westaim reduces ABCP exposure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
Breaking Medicine Technology: